Schering-Plough Section 174 R&E expenditures decreased by 25.8% to $3.82M in Q4 2025 compared to the prior quarter. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase reflects higher R&D investment being capitalized for tax purposes, which will provide future tax shields.
This metric tracks deferred tax assets specifically arising from the capitalization and amortization of research and exp...
Highly relevant for clinical-stage biotechs subject to current tax laws regarding R&D capitalization.
other_deferred_tax_assets_section174re_expenditures| Q4 '24 | Q4 '25 | |
|---|---|---|
| Value | $5.15M | $3.82M |
| QoQ Change | — | -25.8% |
| YoY Change | — | -25.8% |